1. Combination of targeted therapy and immunotherapy in melanoma

   • Christian U. Blank
   • Anna I. Hooijkaas
   • Ton N. Schumacher

   Review 17 August 2011 Pages: 1359 - 1371

   

2. The potential role of thioredoxin 1 and CD30 systems as multiple pathway targets and biomarkers in tumor therapy

   • Anna Maria Berghella
   • Patrizia Pellegrini
   • Ida Contasta

   Perspectives Open access 08 July 2011 Pages: 1373 - 1381

   

3. Low molecular weight hyaluronan preconditioning of tumor-pulsed dendritic cells increases their migratory ability and induces immunity against murine colorectal carcinoma

   • Laura Alaniz
   • Manglio Rizzo
   • Guillermo Mazzolini

   Original article 03 June 2011 Pages: 1383 - 1395

   

4. Immuno-cell therapy with antecedent surgery has superior actuarial survival to immuno-cell therapy without antecedent surgery for advanced cancers

   • Goki Shindo
   • Takayoshi Endo
   • Shigenori Goto

   Original article 03 June 2011 Pages: 1397 - 1403

   

5. Ectonucleotidases CD39 and CD73 on OvCA cells are potent adenosine-generating enzymes responsible for adenosine receptor 2A-dependent suppression of T cell function and NK cell cytotoxicity

   • Sebastian F. M. Häusler
   • Itsaso Montalbán del Barrio
   • Jörg Wischhusen

   Original article 03 June 2011 Pages: 1405 - 1418

   

6. Elevated myeloid-derived suppressor cells in pancreatic, esophageal and gastric cancer are an independent prognostic factor and are associated with significant elevation of the Th2 cytokine interleukin-13

   • Rachel F. Gabitass
   • Nicola E. Annels
   • Gary W. Middleton

   Original article Open access 05 June 2011 Pages: 1419 - 1430

   

7. Involvement of damage-associated molecular patterns in tumor response to photodynamic therapy: surface expression of calreticulin and high-mobility group box-1 release

   • Mladen Korbelik
   • Wei Zhang
   • Soroush Merchant

   Original article 05 June 2011 Pages: 1431 - 1437

   

8. An ADP ribosylation factor-GTPase activating protein negatively regulates the production of proinflammatory mediators in response to lipopolysaccharide

   • Abedul Haque
   • Abu Shadat Mohammod Noman
   • Takashi Yokochi

   Original article 05 June 2011 Pages: 1439 - 1446

   

9. Pilot trial of interleukin-2 and zoledronic acid to augment γδ T cells as treatment for patients with refractory renal cell carcinoma

   • Joshua M. Lang
   • Mahazarin R. Kaikobad
   • Miroslav Malkovsky

   Original article 07 June 2011 Pages: 1447 - 1460

   

10. Myxoma virus combined with rapamycin treatment enhances adoptive T cell therapy for murine melanoma brain tumors

    • Diana L. Thomas
    • Rosalinda Doty
    • Edward J. Roy

    Original article 09 June 2011 Pages: 1461 - 1472

    

11. Th17 and Th17-stimulated CD8⁺ T cells play a distinct role in Th17-induced preventive and therapeutic antitumor immunity

    • Manjunatha Ankathatti Munegowda
    • Yulin Deng
    • Jim Xiang

    Original article 10 June 2011 Pages: 1473 - 1484

    

12. Serum levels of cytoplasmic melanoma-associated antigen at diagnosis may predict clinical relapse in neuroblastoma patients

    • Fabio Morandi
    • Maria Valeria Corrias
    • Vito Pistoia

    Original article 10 June 2011 Pages: 1485 - 1495

    

13. Dendritic cells combining with cytokine-induced killer cells synergize chemotherapy in patients with late-stage non-small cell lung cancer

    • Runbo Zhong
    • Jiajun Teng
    • Hua Zhong

    Original Article 17 June 2011 Pages: 1497 - 1502

    

14. The n3-polyunsaturated fatty acid docosahexaenoic acid induces immunogenic cell death in human cancer cell lines via pre-apoptotic calreticulin exposure

    • Romina Molinari
    • Donatella D’Eliseo
    • Nicolò Merendino

    Short communication 22 July 2011 Pages: 1503 - 1507